An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

M. Bennie; C. Black; V. Cairns; S. Hems; L. Mciver; J. Nicholson; S. Oduro; R. Payne; W. Ramsay

doi:10.1111/j.1742-7843.2009.00437.x

An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

M. Bennie, C. Black, V. Cairns, S. Hems, L. Mciver, J. Nicholson, S. Oduro, R. Payne, W. Ramsay

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Conference Contribution › peer-review

37 Citations (Scopus)

Abstract

A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug and
Therapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

Original language	English
Pages (from-to)	92-92
Number of pages	1
Journal	Basic and Clinical Pharmacology and Toxicology
Volume	105
Issue number	Supp.1
Early online date	26 Jun 2009
DOIs	https://doi.org/10.1111/j.1742-7843.2009.00437.x https://doi.org/10.1002/pds.1806
Publication status	Published - Aug 2009
Event	9th Congress of the European Association for the Clinical Pharmacology and Therapeutics - Edinburgh, United Kingdom Duration: 12 Jul 2009 → 15 Jul 2009

Keywords

medicine
Scotland
consortium
area drug and therapeutics committees
ADTCs

Access to Document

Cite this

Bennie, M., Black, C., Cairns, V., Hems, S., Mciver, L., Nicholson, J., Oduro, S., Payne, R., & Ramsay, W. (2009). An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders. Basic and Clinical Pharmacology and Toxicology , 105(Supp.1), 92-92. https://doi.org/10.1111/j.1742-7843.2009.00437.x, https://doi.org/10.1002/pds.1806

@article{66ddf6eb5a784c48914d81bbdd7f9b0a,

title = "An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders",

abstract = "A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug andTherapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).",

keywords = "medicine, Scotland, consortium, area drug and therapeutics committees, ADTCs",

author = "M. Bennie and C. Black and V. Cairns and S. Hems and L. Mciver and J. Nicholson and S. Oduro and R. Payne and W. Ramsay",

year = "2009",

month = aug,

doi = "10.1111/j.1742-7843.2009.00437.x",

language = "English",

volume = "105",

pages = "92--92",

journal = "Basic and Clinical Pharmacology and Toxicology ",

issn = "1742-7835",

number = "Supp.1",

note = "9th Congress of the European Association for the Clinical Pharmacology and Therapeutics ; Conference date: 12-07-2009 Through 15-07-2009",

}

Bennie, M, Black, C, Cairns, V, Hems, S, Mciver, L, Nicholson, J, Oduro, S, Payne, R & Ramsay, W 2009, 'An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders', Basic and Clinical Pharmacology and Toxicology , vol. 105, no. Supp.1, pp. 92-92. https://doi.org/10.1111/j.1742-7843.2009.00437.x, https://doi.org/10.1002/pds.1806

TY - JOUR

T1 - An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

AU - Bennie, M.

AU - Black, C.

AU - Cairns, V.

AU - Hems, S.

AU - Mciver, L.

AU - Nicholson, J.

AU - Oduro, S.

AU - Payne, R.

AU - Ramsay, W.

PY - 2009/8

Y1 - 2009/8

N2 - A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug andTherapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

AB - A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug andTherapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

KW - medicine

KW - Scotland

KW - consortium

KW - area drug and therapeutics committees

KW - ADTCs

U2 - 10.1111/j.1742-7843.2009.00437.x

DO - 10.1111/j.1742-7843.2009.00437.x

M3 - Conference Contribution

SN - 1742-7835

VL - 105

SP - 92

EP - 92

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

IS - Supp.1

T2 - 9th Congress of the European Association for the Clinical Pharmacology and Therapeutics

Y2 - 12 July 2009 through 15 July 2009

ER -